关于 Tolerx, inc.

关于公司

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.